[Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit].
U A MаrkinaDarya S FominaM S LebedkinaTat'yana S KruglovaAnton A ChernovA I ZagrebnevaZinaida Yu MutovinaAlexander V KaraulovEkaterina AlexeevaMar'yana A LysenkoPublished in: Terapevticheskii arkhiv (2022)
In real clinical practice, the efficacy and safety of regdanvimab in patients at high risk of severe COVID-19 was confirmed once again, with a positive clinical result observed in a mixed cohort by the causative agent omicron and delta strain.